Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer

Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K- α / δ activity that has demonstrated clinical activity and manageable safety when administered as monotherapy in a phase II study. Combination therapy may overcome compensatory signalling th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2018-02, Vol.118 (4), p.462-470
Hauptverfasser:	Kim, R D, Alberts, S R, Peña, C, Genvresse, I, Ajavon-Hartmann, A, Xia, C, Kelly, A, Grilley-Olson, J E
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase 631/154/109/1940 631/67/1059/153 692/308/153 Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biliary tract Biliary Tract Neoplasms - drug therapy Biliary Tract Neoplasms - genetics Bioindicators Biomarkers Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cell cycle Chemotherapy Cholangiocarcinoma Cisplatin Cisplatin - administration & dosage Cisplatin - adverse effects Clinical Study Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Drug Administration Schedule Drug Resistance Enzyme inhibitors Epidemiology Female Gallbladder Gastric cancer Gemcitabine Homology Humans Hyperglycemia Kinases Male Maximum Tolerated Dose Middle Aged Molecular Medicine Mutation Nausea Oncology Peritoneum Pharmacokinetics Phosphatidylinositol 3-Kinases - genetics Proteins Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) - genetics PTEN Phosphohydrolase - genetics Pyrimidines - administration & dosage Pyrimidines - adverse effects Quinazolines - administration & dosage Quinazolines - adverse effects Safety Safety management Signal transduction Standard deviation Tensin Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!